Compound research

BPC-157: A Research Overview

Aminent Labs Research·Updated July 2026·6 min read·For Research Use Only

BPC-157 is a synthetic 15-amino-acid peptide (a "pentadecapeptide") that has been the subject of a substantial body of preclinical, cell-culture, and animal-model research. This page summarizes its biochemistry, the mechanisms investigated in the laboratory literature, and how research-grade material is characterized. The information below is provided strictly for educational and research-use-only (RUO) purposes; BPC-157 is not a drug, dietary supplement, or approved therapy, and nothing here describes or endorses human use.

What is BPC-157?

BPC-157 is a synthetic pentadecapeptide, meaning it is composed of fifteen amino acids joined in a single chain. Its reported amino-acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, corresponding to a molecular formula of approximately C62H98N16O22 and a monoisotopic molecular weight of roughly 1419 g/mol. The abbreviation "BPC" stands for "Body Protection Compound," and "157" refers to the position of the fragment within a larger parent sequence.

BPC-157 is described in the literature as a partial sequence derived from a protein originally identified in gastric juice. Importantly, the isolated 15-residue peptide is a synthetic construct produced by solid-phase peptide synthesis rather than a molecule extracted intact from tissue. A frequently noted property in the research literature is its relative stability, including reported resistance to degradation under low-pH conditions similar to gastric juice, which has made it a convenient subject for in-vitro and preclinical studies.

Mechanisms studied in research

Several molecular mechanisms have been investigated in cell-culture and animal-model studies. A recurring theme in the preclinical literature is an association with angiogenesis-related signaling. In endothelial-cell assays, BPC-157 has been reported to modulate vascular endothelial growth factor receptor 2 (VEGFR2) expression and internalization, with downstream signaling described through the VEGFR2-Akt-eNOS axis. Notably, some studies report changes in VEGFR2 signaling without a corresponding increase in VEGF-A itself.

A second area of mechanistic study concerns the nitric oxide (NO) system. Research using isolated vessel preparations has described concentration-dependent, nitric-oxide-dependent effects on vasomotor tone, reported to involve the Src-caveolin-1-endothelial nitric oxide synthase (eNOS) pathway. Additional preclinical reports have examined interactions with growth-factor pathways, including growth-hormone-receptor expression in fibroblast cultures, as well as modulation of inflammatory-cytokine markers. These findings are drawn from in-vitro systems and animal models; the mechanisms remain areas of active investigation and should not be extrapolated to humans.

Areas of preclinical investigation

The published preclinical literature on BPC-157 spans a range of tissue-injury and gastrointestinal research contexts, studied predominantly in rodent models. Gastrointestinal research has examined outcomes in animal models of gastric mucosal injury, NSAID-associated gut irritation, colitis, intestinal anastomosis, and fistula healing, where the peptide has been used as an experimental agent to probe tissue-repair processes.

A separate cluster of studies has investigated musculoskeletal and connective-tissue repair in animals, including rodent models of tendon, ligament, muscle, and bone injury, as well as myotendinous-junction and muscle-to-bone reattachment models. Other reports have explored neural-tissue and pain-modulation endpoints in rodents. Across this literature, the work is characterized as preclinical: evidence is derived from cell cultures and animal experiments, robust human clinical-trial data are limited, and the findings describe research observations rather than established effects in people.

Stability, handling & storage

Research-grade BPC-157 is typically supplied as a lyophilized (freeze-dried) powder. In this dry, moisture-free form the peptide is generally regarded as the most stable, and lyophilized material is commonly stored frozen (for example, at -20 C) and protected from light and humidity for long-term storage in the laboratory. As with most peptides, repeated freeze-thaw cycles are usually avoided.

For in-vitro experimental work, lyophilized peptide is reconstituted in an appropriate laboratory solvent before use; the specific buffer or diluent and working concentration are determined by the requirements of the assay. In general terms, peptides in solution are less stable than in the dry state, and BPC-157 has been reported to degrade, isomerize, or rearrange measurably in reconstituted solution over a period of days to weeks depending on conditions. Reconstituted stock is therefore commonly kept cold, used within a limited window, and characterized freshly when accuracy of concentration matters. These are general laboratory-handling considerations for research material and do not constitute preparation instructions for any use in humans or animals outside of a controlled research setting.

How research-grade peptides are characterized

Two analytical techniques form the backbone of peptide quality control. High-performance liquid chromatography (HPLC), typically reverse-phase on a C18 column with an acetonitrile-water gradient and UV detection near 220 nm, is used to assess purity by separating the target peptide from synthesis-related impurities, truncated fragments, and degradation products. A purity figure (for instance, at least 98-99% by HPLC) indicates how much of the material is the intended peptide versus contaminants.

Mass spectrometry (such as ESI-MS or MALDI-TOF MS) is used to confirm identity by measuring the molecular mass and comparing it against the expected value for BPC-157. Beyond purity and identity, a meaningful specification also accounts for net peptide content, since lyophilized material can include residual water, counter-ions, and salts, meaning the mass in a vial is not entirely peptide. A Certificate of Analysis (COA) documenting HPLC purity, mass-spectrometric identity, and net peptide content allows researchers to verify what they are actually working with and to make accurate, reproducible calculations for in-vitro experiments.

How research-grade BPC-157 is synthesized

Research-grade BPC-157 is not extracted from tissue. It is assembled by solid-phase peptide synthesis (SPPS), the standard method for peptides of this length, in which the chain is built one residue at a time on an insoluble resin support. Each cycle deprotects the growing chain's N-terminus and couples the next protected amino acid; at the end the completed peptide is cleaved from the resin, the side-chain protecting groups are removed, and the crude product is purified — for a peptide of this class, typically by preparative reverse-phase HPLC.

Understanding this matters for reading a specification, because the characteristic impurities in a synthetic peptide are a direct consequence of the chemistry. If a coupling step is incomplete, some chains lack a residue, producing a deletion sequence of very similar mass and often similar retention time. Chains that stop growing altogether yield truncation sequences. BPC-157's sequence is unusually proline-rich (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val contains five prolines, including a Pro-Pro-Pro run), and consecutive prolines are well documented as sterically demanding couplings in SPPS — which is precisely the kind of sequence feature that makes a rigorous purity method worth insisting on. The general families of synthesis- and storage-derived impurities, and how each is detected, are covered in Peptide Impurities Explained.

Reading a BPC-157 certificate of analysis

A COA is only useful if the reader knows which numbers to check against what. For this compound the specific expectations are:

Identity by mass. The measured mass should correspond to the expected value for the 15-residue sequence — on the order of 1419 g/mol for the free peptide. Note that a mass spectrum reports the monoisotopic mass (calculated from the single most abundant isotope of each element) while reference tables often quote an average mass; for a peptide this size the two differ slightly, so a small discrepancy between a COA figure and a textbook value is usually a difference of convention rather than a failed identification.
Purity by HPLC. An area-percent figure at 220 nm, where the peptide bond absorbs. The number is only meaningful alongside the method — gradient, column, and run time — because a gradient too steep to resolve a deletion sequence from the main peak will report a flattering result. HPLC vs mass spectrometry explains why purity and identity are separate questions that need separate tests.
Net peptide content. The fraction of the vial's mass that is actually peptide, the remainder being residual water, counter-ions, and salts. This is the figure used to calculate a stock concentration accurately, and it is routinely lower than the purity figure — see Net Peptide Content vs. Purity.
Counter-ion. Peptides purified by reverse-phase HPLC are commonly isolated as a salt — frequently acetate or trifluoroacetate (TFA), depending on the mobile phase and any subsequent salt exchange. The counter-ion contributes mass that is not peptide, which is one of the main reasons net content and gross vial mass diverge.

Aminent Labs publishes a per-lot certificate for each batch; current reports are available on the certificates of analysis page, and lot documentation for this compound accompanies the BPC-157 product listing. For a field-by-field walkthrough of a certificate, see How to Read a Peptide COA.

Points of confusion in the literature

Several recurring ambiguities are worth separating out, because they cause researchers to compare figures that are not directly comparable.

The peptide versus its parent protein. BPC-157 is a defined 15-residue synthetic construct, not the intact protein from which the sequence was originally described. Literature referring to the parent gastric protein is not describing the same molecule, and mass or activity figures from one do not transfer to the other.

Salt form versus free peptide. The same lot can be described by its free-peptide mass or by the mass of the isolated salt. Molar calculations should use the free-peptide mass together with the lot's stated net peptide content; using gross powder mass instead systematically overstates the amount of peptide present.

Marketing descriptors that are not chemical specifications. Terms such as "stable" or "enhanced" applied to a research peptide are not defined analytical terms and carry no specification meaning. What is verifiable is what appears on the certificate: sequence-consistent mass, an area-percent purity figure with its method, and a net peptide content. Claims that cannot be tied to a measurement on a per-lot report should be treated as unverified, a point developed in Third-Party Peptide Testing.

Compounds studied alongside it. Parts of the preclinical connective-tissue literature discuss BPC-157 and the Thymosin Beta-4 fragment TB-500 in adjacent contexts, and the two are supplied together as a paired research vial. They are chemically unrelated molecules with different sequences, masses, and characterization requirements, and each requires its own certificate; being discussed in the same paper is not evidence of a shared mechanism.

FAQ

What is BPC-157? BPC-157 is a synthetic pentadecapeptide (a chain of 15 amino acids) with a molecular weight of approximately 1419 g/mol. Its name stands for "Body Protection Compound," and it is described as a partial sequence derived from a protein found in gastric juice. It is studied in in-vitro and animal-model research and is intended for research use only.

Is BPC-157 approved for any use? No. BPC-157 is an unapproved research chemical. It is not a drug, dietary supplement, or approved therapy, and it has not been authorized by regulators such as the FDA for the treatment, prevention, or diagnosis of any condition in humans. It is offered strictly for research-use-only (RUO) laboratory purposes and is not intended for human or veterinary use.

How should BPC-157 be stored? In its lyophilized (freeze-dried) powder form, BPC-157 is generally most stable and is typically kept frozen (for example at -20 C), protected from light and moisture, for long-term storage. Once reconstituted for in-vitro work, peptide solutions are less stable, are usually kept cold, and are used within a limited window.

How is purity verified? Purity is verified primarily by reverse-phase HPLC, which separates the target peptide from impurities and degradation products, while mass spectrometry (ESI-MS or MALDI-TOF) confirms the molecule's identity by its measured mass. A Certificate of Analysis (COA) reporting HPLC purity, mass-spec identity, and net peptide content lets researchers confirm the material's quality before use.

Why is the net peptide content lower than the purity figure? They measure different things. HPLC purity is the proportion of the peptide present that is the intended sequence, expressed as an area percent. Net peptide content is the proportion of the vial's total mass that is peptide at all — the balance being residual water, counter-ions such as acetate or TFA, and salts left from purification. A lot can therefore be 99% pure by HPLC and still be well under 99% peptide by mass, which is why molar calculations use the net-content figure.

Is BPC-157 the same molecule as TB-500? No. They are chemically unrelated peptides with different sequences and different molecular weights — BPC-157 is a 15-residue synthetic pentadecapeptide of roughly 1419 g/mol, while TB-500 is the acetylated Thymosin Beta-4 fragment Ac-LKKTETQ of roughly 889 g/mol. They appear together in parts of the preclinical connective-tissue literature and are supplied as a paired research vial, but each is a distinct compound requiring its own identity and purity documentation.

References & further reading

Related research

Peptide Storage and Stability

How lyophilized and reconstituted peptides degrade, and how to store them.

How to Read a Peptide COA

What each field on a certificate of analysis means.

What Is Research Use Only (RUO)?

What the RUO designation means for lab buyers.

For Research Use Only. All Aminent Labs materials are intended solely for in-vitro research and laboratory use — not for human or veterinary use. View the product page, browse the catalog, or review certificates of analysis.